Real life experience of molnupiravir as a treatment of SARS-CoV-2 infection in vaccinated and unvaccinated patients: a letter on its effectiveness at preventing hospitalization

BACKGROUND: The SARS-CoV-2 pandemic has prompted clinicians to develop an early and effective treatment of viral infections. To date, vaccines, monoclonal antibodies, and antivirals are the cornerstone of therapy for SARS-CoV-2. AIFA approved the prescription of molnupiravir on 30/12/2021. Molnupira...

Descripción completa

Detalles Bibliográficos
Autores principales: Scioscia, Giulia, De Pace, Cosimo Carlo, Giganti, Giulio, Tondo, Pasquale, Foschino Barbaro, Maria Pia, Lacedonia, Donato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713130/
https://www.ncbi.nlm.nih.gov/pubmed/36454535
http://dx.doi.org/10.1007/s11845-022-03241-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713130/
https://www.ncbi.nlm.nih.gov/pubmed/36454535
http://dx.doi.org/10.1007/s11845-022-03241-1

Ejemplares similares